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Abstract  22 
Introduction. Polymicrobial infections commonly occur within the lower respiratory 23 
tract, although there is a paucity of information regarding the host response to multi-24 
species pathogens. Deleterious effects occur frequently as a result of microbe-25 
microbe interactions, although an unexpected protective effect of Staphylococcus 26 
aureus has been observed in cystic fibrosis patients co-infected with Pseudomonas 27 
aeruginosa or species belonging to the Burkholderia cepacia complex.  28 
Aim. This study aims to investigate the differences in host responses to mono- and 29 
co-infection with S. aureus and B. cenocepacia in 16HBE human airway epithelial cells, 30 
interpret the host receptor and signalling events targeted by S. aureus, and 31 
characterise staphylococcal immunomodulatory factors. 32 
Methodology and Results. The results show that B. cenocepacia activates MAPK 33 
and NF-κB signalling pathways, subsequently eliciting a robust interleukin (IL)-8 34 
production. However, when airway epithelial cells were co-treated with live B. 35 
cenocepacia bacteria and S. aureus supernatants (conditioned medium), the pro-36 
inflammatory response was attenuated. This anti-inflammatory effect was widely 37 
exhibited in S. aureus isolates tested and was mediated via reduced MAPK and NF-38 
κB signalling but not via the IL-1 receptor or the tumour necrosis factor receptor 39 
modulation. The staphylococcal effectors were characterised as small, heat-stable, 40 
non-proteinaceous, and not cell wall-related factors. 41 
Conclusion. This study demonstrates for the first time the host response in a S. 42 
aureus / B. cenocepacia co-infection model and provides insight into a staphylococcal 43 
immune evasion mechanism, as well as a therapeutic intervention for excessive 44 
inflammation.  45 
 3 
Introduction 46 
Lower respiratory tract infections are a major cause of morbidity and mortality globally 47 
(Troeger et al., 2017). Individuals with an immune deficiency, chronic obstructive 48 
pulmonary disease, or cystic fibrosis (CF) are particularly prone to such respiratory 49 
infections (Pragman et al., 2016).  50 
The opportunistic pathogen Staphylococcus aureus is one of the major threats that is 51 
commonly associated with respiratory infections both in hospital and community 52 
environments (Tong et al., 2015). This is not only due to a wide range of virulence 53 
factors deployed by S. aureus (Haaber et al., 2017; Thammavongsa et al., 2015), but 54 
also the rapid emergence of multidrug-resistant strains. S. aureus that gains 55 
resistance to β-lactam antibiotics as a consequence of adopting the staphylococcal 56 
cassette chromosomal mec element, becomes methicillin-resistant S. aureus (MRSA). 57 
This emergence is posing serious challenges to antimicrobial therapy as patients 58 
harbouring MRSA are associated with worse clinical prognosis compared to those who 59 
never have MRSA (Dasenbrook et al., 2010; Moran et al., 2012).   60 
Burkholderia cepacia complex (Bcc) is a major threat for immunocompromised 61 
individuals such as CF patients, as it is transmissible between patients who can 62 
develop ‘cepacia syndrome’ which is a fatal exacerbation of respiratory function as a 63 
result of bacteraemia (Hauser and Orsini, 2015; Kenna et al., 2017; LiPuma et al., 64 
1988; Palfreyman et al., 1997). Together with Pseudomonas aeruginosa and other 65 
species, Bcc are non-fermenting Gram negative bacilli which are not able to utilise 66 
glucose in the absence of oxygen. Pathogens of these bacteria have become an 67 
increasing challenge in hospital-acquired infections due to the high magnitude of 68 
intrinsic antibiotic resistance (Oliveira et al., 2017; Shommu et al., 2015). While the 69 
prevalence of S. aureus infection is about 60% among CF patients younger than 2 70 
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years and peaks between 11 to 17 years old, most Bcc colonisation is acquired after 71 
the age of 18 (Cystic Fibrosis Foundation, 2017). Bcc bacteria express a wide  range 72 
of virulence factors to facilitate the infection process, such as cable pili, flagella, 73 
several secretion systems or homologous structures (Leitão et al., 2010; Urban et al., 74 
2005; 2004). In addition, the unusual modification of lipopolysaccharide (LPS) at least 75 
partially contributes to the virulence of Bcc. Acylation of lipid A contributes to a much 76 
stronger pro-inflammatory response induced by Bcc LPS even compared to LPS from 77 
P. aeruginosa and Escherichia coli (De Soyza et al., 2008). The resulting cytokine 78 
storm attracts a large number of immune cells such as neutrophils and mononuclear 79 
cells to the lung. If the acute inflammatory response is not resolved, it causes tissue 80 
injury which leads to pulmonary fibrosis and possibly develops into a chronic 81 
inflammation (Tisoncik et al., 2012).  82 
Chronic pulmonary infection is commonly associated with colonisation with more than 83 
one microorganism, but little is known regarding the complicated mechanisms of host-84 
microbe and microbe-microbe interactions and their impact on disease. The microbe-85 
microbe interaction can be synergistic or antagonistic in nature and both forms of 86 
interaction can lead to increased antibiotic resistance and virulence (Orazi and 87 
O'Toole, 2017; Perez et al., 2014; Ramsey and Whiteley, 2009). Although many 88 
studies have reported worse clinical outcomes resulting from microbe-microbe 89 
interactions (Bragonzi et al., 2012; Fugère et al., 2014; Korgaonkar et al., 2013), this 90 
is not always the case. Contrary to the negative impact by Bcc and P. aeruginosa, S. 91 
aureus co-infection is positively associated with a relatively better lung function, higher 92 
survival rate, and delayed lung disease progression (Emerson et al., 2002; Liou et al., 93 
2001; Mayer-Hamblett et al., 2007; Nixon et al., 2001). An in vivo study that mimicked 94 
the sequential acquisition of early S. aureus and late P. aeruginosa in the murine lung 95 
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shows that pre-infection with S. aureus significantly reduced inflammation and the 96 
incidence of mortality caused by P. aeruginosa but enhanced P. aeruginosa 97 
persistence (Cigana et al., 2018). We thus hypothesised that the protective effect of 98 
S. aureus results from dampening the inflammatory response towards Bcc by 99 
interfering with the host signalling pathways. Therefore, evaluating whether S. aureus 100 
colonisation favours the host and understanding the mechanism behind the 101 
unexpected protective effect of S. aureus may shed light on novel therapies for 102 
persistent infections.   103 
In this study, in order to gain insights of the host response to S. aureus / B. 104 
cenocepacia co-colonisation, we assessed the effect of B. cenocepacia on the host 105 
signalling cascade and inflammatory responses in airway epithelial cells, compared to 106 
that of co-infection. Further we identified the host target of staphylococcal 107 
immunomodulatory factors, and the nature of immunomodulatory molecules released 108 
by S. aureus, highlighting the anti-inflammatory modulation of S. aureus during Bcc 109 
co-infection and potential effects on the clinical outcome.  110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
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Material and methods 119 
Bacteria strains and culture 120 
The bacterial strains used in this study are listed in Table 1. Bacteria were cultured in 121 
LB broth (Thermo Fisher Scientific) at 37°C with shaking. Bacterial supernatants were 122 
collected and filtered through a 0.2 μm membrane. Where indicated, supernatants 123 
were heat-treated by incubating at 95°C for 10 minutes. Heat-killed S. aureus were 124 
prepared by resuspending the overnight culture to the desired multiplicity of infection 125 
(MOI) in DMEM (Gibco, Thermo Fisher Scientific), and heating at 100°C for 1 hour. 126 
Proteinase K immobilised on Eupergit® C (Sigma-Aldrich) was used at a concentration 127 
of 100 μg/mL in Tris-Cl (50 mM, pH 8) / CaCl2 (10 mM) at 37°C for 1 hour. At the end 128 
of digestion, proteinase K was removed by centrifugation at 250 g for 10 minutes. 129 
Inactivated proteinase K was prepared by heating at 100°C for 1 hour.   130 
Fractionated products of S. aureus were prepared by submitting supernatants to 10-131 
kDa- and 3-kDa-cutoff centrifugal concentrators (Vivaspin 20, Sigma-Aldrich), 132 
centrifuged at 5000 g for 17 minutes and 180 minutes respectively following the 133 
manufacturer’s instructions. Supernatants were separated into three fractions: >10000 134 
molecular weight cut-off (MWCO), 3000-10000 MWCO, and <3000 MWCO. Filtrates 135 
and concentrates were adjusted to the original volume with fresh LB, followed by filter 136 
sterilisation.  137 
Human airway epithelial cell culture  138 
Human bronchial epithelial 16HBE (obtained from Prof Dieter C. Gruenert, University 139 
of California San Francisco) and human airway epithelial Calu-3 (ATCC) were 140 
maintained in DMEM, supplemented with 10% heat-inactivated foetal bovine serum, 141 
100 units/mL penicillin, and 100 μg/mL streptomycin (all from Gibco, Thermo Fisher 142 
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Scientific). Cells were incubated at 37°C in a humidified atmosphere with 5% CO2. IL-143 
1β and tumour necrosis factor (TNF) α (Peprotech) were used at the concentrations 144 
indicated.   145 
Cell viability assay 146 
The cell viability assay with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 147 
bromide; Sigma-Aldrich) assay was used as described before (Wachsmann and 148 
Lamprecht, 2012). Briefly, 16HBE cells were plated in 96-well plates (5000 cells/well) 149 
and incubated for 24 hours. Next, the medium was replaced by 10% S. aureus 150 
supernatants for 24 hours. After incubating cells with 12 mM MTT for 2 hours, 151 
formazan formed in viable cells was dissolved in DMSO for 10 minutes before the 152 
optical density was read at 550 nm. 153 
Detection of Cytokine Production 154 
At the end of stimulation, conditioned medium of 16HBE cells was collected and the 155 
concentration of interleukin (IL)-8 was quantified using Maxisorp ELISA plates (Nunc, 156 
Thermo Fisher Scientific) and a commercially available ELISA kit (eBioscience, 157 
Thermo Fisher Scientific) according to the manufacturer’s instructions.  158 
Western Blot Analysis 159 
Following stimulation, cell lysates were prepared and the concentration of total protein 160 
was quantified using PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific). 161 
Protein samples were resolved on an SDS-PAGE gel, and immunoblotted on a 162 
nitrocellulose membrane (Bio-Rad). The membrane was probed with antibodies anti 163 
phospho-NF-κB-p65, phospho-p38, phospho-Erk, and p38 (Cell Signaling 164 
Technology), followed by incubation with secondary antibodies (Li-Cor Biosciences). 165 
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Quantitative analysis of the signal was performed using the Li-Cor Odyssey Clx 166 
imaging system.  167 
Statistical Analysis 168 
Data were expressed as the mean ± standard error of the mean (SEM) for n=3 169 
independent biological repeats. Results were compared using Graphpad Prism and 170 
one-way or two-way ANOVA, followed by Tukey or Dunnett’s multiple comparisons 171 
test, with p<0.05 considered significant.  172 
 173 
 174 
 175 
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 183 
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 185 
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Results 188 
B. cenocepacia-stimulated IL-8 response is suppressed by S. aureus products. 189 
IL-8 plays an important role at the early stage of infection by chemoattracting 190 
granulocytes such as neutrophils (Perret et al., 2012). Hence, the level of IL-8 is a 191 
biomarker of pro-inflammatory responses and inflammation (Dennehy et al., 2017; 192 
Palfreyman et al., 1997). B. cenocepacia induced a robust increase in IL-8 response 193 
in 16HBE cells (Figure 1A). Although supernatants (in LB medium) of S. aureus 194 
MRSA252 or MSSA NCTC 6571 did not change IL-8 production compared to the 195 
control, they significantly downregulated IL-8 induced by B. cenocepacia (23% and 31% 196 
less than the B. cenocepacia-treated group, respectively). In contrast, heat-killed S. 197 
aureus did not have the suppressing effect (Figure 1B).  198 
The same experiments were done with a collection of S. aureus isolates, either 199 
supernatants (Figure 1C). Supernatants from all the tested isolates downregulated the 200 
level of IL-8 production by  different amounts (5.4%-38.0%).  Although some of the 201 
differences were small, consistent changes were seen within each experiment and 202 
these were statistically significant (p<0.05). The ability of heat-killed bacteria to inhibit 203 
B. cenocepacia-elicited IL-8 production (Figure 1D).  However, whole heat-killed 204 
bacteria had no effect on B. cenocepacia-induced IL-8 production. These data indicate 205 
that anti-inflammatory activity in these experiments is expressed in secreted products 206 
but not heat-stable S. aureus cell surface structures. This contrasts with the nasal 207 
isolate S. aureus anti-inflammatory activity reported by Peres et al. (2015), which was 208 
exhibited by whole bacteria subjected to the same heat treatment conditions.  209 
To confirm the suppressing effect is not due to cell damage, an MTT assay was used 210 
to assess cell viability (Figure 1E). For the majority of S. aureus strains, their 211 
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supernatants did not cause epithelial cell damage, indicating that there was no 212 
causality between IL-8 suppression and induction of epithelial cell damage. 213 
Exceptions were SH1000 and RN4220 which did reduce cell viability and, interestingly, 214 
these alone caused a doubling in IL-8 production (Figure 1C). 215 
MSSA NCTC 6571 products block MAPK p38 and Erk, and NF-κB signalling 216 
activated by B. cenocepacia 217 
The recognition of conserved microbial structures of pathogens by pattern recognition 218 
receptors leads to activation of MAPK and NF-κB signalling pathways, subsequently 219 
initiating the expression of pro-inflammatory genes to mount an immune response 220 
(Pandey et al., 2014). NF-κB and MAPK pathways contribute to IL-8 expression at 221 
multiple levels (Hoffmann et al., 2002). Since B. cenocepacia induced a strong IL-8 222 
production, the effects of B. cenocepacia on MAPK and NF-κB signalling in 16HBE 223 
cells were assessed. Cells were challenged with B. cenocepacia at an MOI of 5 from 224 
5 minutes to 180 minutes (Figure 2 A-D). For the MAPK family, phosphorylation of p38 225 
was maximal at 120 minutes (200% more than time 0), while phosphorylation of Erk 226 
peaked at 5 minutes (156% more than time 0), followed by a decrease and then a 227 
secondary rise at 120 minutes (133% more than time 0). For NF-κB signalling, B. 228 
cenocepacia upregulated phosphorylation of p65, particularly after 120 minutes.  229 
In order to study the modulation on host signalling by this co-stimulation model, 16HBE 230 
cells were treated with B. cenocepacia (5 MOI) and 10% S. aureus supernatant for 2 231 
hours (Figure 2E-H). B. cenocepacia led to phosphorylation of p38, Erk, and p65, 232 
whereas S. aureus supernatant alone did not change any tested signalling events.  233 
Notably, MSSA NCTC 6571 but not MRSA252 supernatant reduced phosphorylation 234 
of p38, Erk and p65 stimulated by B. cenocepacia. The reduction in p38 and p65 235 
signalling was significant compared with B. cenocepacia alone (p<0.05).  This strain 236 
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selectivity is consistent with the differential inhibition of the pro-inflammatory response 237 
(Figure 1A) by MSSA NTCT 6571 and MRSA252. Therefore, these findings suggest 238 
that MSSA NCTC 6571 supernatant may suppress the pro-inflammatory effect of B. 239 
cenocepacia by inhibiting MAPK and NF-κB signalling. 240 
Characterisation of anti-inflammatory factors in S. aureus supernatant 241 
To investigate the nature of anti-inflammatory components, S. aureus supernatants 242 
were heated at 95°C for 10 minutes. These heat-treated supernatants were still able 243 
to inhibit the B. cenocepacia-stimulated IL-8 response (Figure 3A), indicating that the 244 
components are heat stable.  245 
Further, S. aureus supernatants were treated with solid-phase proteinase K for 1 hour 246 
at 37°C before removal to avoid any effect of the proteinase on released IL-8. 247 
Proteinase K-digested supernatants did not restore IL-8 secretion caused by B. 248 
cenocepacia; rather, IL-8 secretion was nearly reduced to the baseline (Figure 3B). 249 
Further, the 16HBE cultures incubated with proteinase-treated supernatant alone did 250 
not inhibit basal IL-8 levels (Figure 3B), indicating that no amounts of protease K was 251 
carried over into the production assay. Heat-inactivated proteinase K-treated 252 
supernatants displayed similar inhibition level as untreated supernatants (Figure 1A), 253 
indicating the components are either non-proteinaceous or proteinase K-resistant.  254 
To assess the approximate molecular weight of the secretory S. aureus components 255 
causing a reduction in B. cenocepacia-induced IL-8 production, S. aureus 256 
supernatants were separated into different molecular cut-off fractions using selective 257 
membranes (Figure 3C). Components in the supernatants with a molecular weight 258 
less than 3 kDa, but not above 3 kDa  reduced IL-8 production back to the same level 259 
as the control, which indicates the anti-inflammatory factors are small molecules.  260 
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As staphylococcal virulence factors (such as SpA and Panton-Valentine Leucocidin) 261 
target the IL-1 receptor (IL-1R) and tumour necrosis factor receptor (TNFR), leading 262 
to IL-8 expression (Gomez et al., 2004; Labrousse et al., 2014), in order to elucidate 263 
whether the S. aureus-induced anti-inflammatory response was selective for bacterial 264 
stimuli, 16HBE cells were treated with IL-1β and TNFα, resulting in the same amount 265 
of IL-8 as the B. cenocepacia-treated group (Figure 3D). However, contrary to the 266 
reduction seen with S. aureus supernatant and J2315 co-stimulation, S. aureus 267 
supernatants did not suppress IL-1β / TNFα-induced IL-8 production, indicating that 268 
IL-1R or TNFR signalling is not associated with this process and the suppressive effect 269 
appears to be targeted toward pathways involved in the B cenocepacia IL-8 response. 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
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Discussion 283 
This study is the first to demonstrate the host response caused by S. aureus / B. 284 
cenocepacia co-infection in airway epithelial cells. We demonstrate that S. aureus 285 
secreted products, but not cell wall-related components are able to suppress the pro-286 
inflammatory response induced by B. cenocepacia. The active compound(s) are 287 
primarily characterised as small, heat-stable, non-proteinaceous, and targeting MAPK 288 
and NF-κB signalling.   289 
Previous studies have concentrated on the interactions between S. aureus and P. 290 
aeruginosa as they are two prevalent pathogens involved in CF lung infections 291 
(Ahlgren et al., 2015; Baldan et al., 2014; Chekabab et al., 2015; DeLeon et al., 2014; 292 
Fugère et al., 2014; Orazi and O'Toole, 2017). However, the impact of S. aureus / Bcc 293 
interactions on host responses has never been assessed. Herein, we demonstrate 294 
that in the context of S. aureus / B. cenocepacia co-infection, supernatants from S. 295 
aureus isolates subverted B. cenocepacia live bacteria-induced IL-8 production in 296 
airway epithelial cells, suggesting that S. aureus releases anti-inflammatory 297 
compounds into the extracellular milieu. This effect of S. aureus provides a possible 298 
explanation of the protective effect of S. aureus colonisation on lung function and 299 
patient survival (Liou et al., 2001; Mayer-Hamblett et al., 2007). 300 
Interestingly, all the supernatants from S. aureus isolates tested were able to subvert 301 
B. cenocepacia-induced IL-8 production (p<0.05). Even hyperinflammatory isolates 302 
such as SH1000 and RN4220, where the supernatants induced strong IL-8 production 303 
(Figure 1C), were able to reduce the inflammatory response, indicating the 304 
components may be widely expressed in S. aureus. The secretome of S. aureus 305 
involves a large arsenal of immune evasion factors that inhibit complement, 306 
chemotaxis, phagocytosis, and induce neutrophil lysis. A whole genome study divided 307 
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88 S. aureus isolates into 25 clonal complex lineages and investigated 43 immune 308 
evasion genes (McCarthy and Lindsay, 2013). The results revealed that although 309 
genes encoding leucocidin are highly conserved, there are variants among other 310 
genes, indicating each lineage applies different strategies and functions of immune 311 
evasion.  312 
The MAPK family and NF-κB signalling pathways are known to play key roles in the 313 
host response to bacterial pathogens by regulating the expression of cytokines and 314 
chemokines (Krachler et al., 2011). However, pathogens have evolved to exploit these 315 
pathways. For example, B. cenocepacia K56-2 can significantly upregulate 316 
phosphorylation of Akt, Erk, and NF-κB in 16HBE cells within 30 minutes of stimulation 317 
(Gillette et al., 2013). In parallel, B. cenocepacia BC7 activates phosphorylation of p38 318 
and JNK in CF bronchial epithelial IB3 cells, whereas these pathways remain 319 
unphosphorylated in contact with an environmental B. cepacia strain (Sajjan et al., 320 
2008). As K56-2 and BC7 both belong to the highly virulent ET-12 lineage, this 321 
indicates that hyperactivation of host signalling is related to more severe lung 322 
inflammation caused by B. cenocepacia isolates.  323 
In our model, B. cenocepacia caused phosphorylation of p38, Erk, and p65 at 120 324 
minutes post-infection. Of note, after a transient increase at 5 minutes post-infection, 325 
phosphorylation of Erk peaked again at 120 minutes. The similar bi-phasic activation 326 
pattern of Erk and p38 was observed in the response to B. pseudomallei both in vitro 327 
and in vivo (D’Elia et al., 2017). Thirty-minutes post-infection, murine alveolar 328 
macrophages exhibited transient phosphorylation of p38 and Erk1, and at 2 h post-329 
infection exhibited sustained activation. As Erk regulates apoptosis in response to 330 
oxidative stress (Li et al., 2016), D’Elia et al. (2017) proposed that the transient 331 
activation at the early stage is associated with host defence, while during the latter 332 
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stage of infection host cells might initiate apoptosis as indicated by continuous Erk 333 
activation, and thereby B. pseudomallei gains time for intracellular proliferation by 334 
delaying apoptosis through modulate the dynamics of Erk activation.  335 
Upon co-stimulation with B. cenocepacia live bacteria and S. aureus supernatant, 336 
activation of MAPK and NF-κB was assessed where MSSA NCTC 6571 supernatant 337 
abolished phosphorylation of p38, Erk, and p65 caused by B. cenocepacia. MRSA252 338 
supernatant did not affect either baseline or B. cenocepacia-induced phosphorylation, 339 
which correlates with its lower inhibitory ability on IL-8 production compared to MSSA 340 
NCTC 6571. Our results are in partial agreement with the results displayed by 341 
Chekabab et al., (2015) as they showed S. aureus supernatants inhibited P. 342 
aeruginosa supernatant-induced inflammatory response through blocking NF-κB 343 
activation but not p38. However, Chekabab et al. (2015) stimulated airway epithelial 344 
Beas-2B cells with synthetic Toll-like receptor (TLR)-2/1 agonist Pam3CSK4 but not P. 345 
aeruginosa, but bacteria themselves contain far more complicated ligands which could 346 
potentially activate the MAPK family. Additionally, the downstream signalling cascades 347 
engaged in the anti-inflammatory response may be cell type-specific. For example, in 348 
human peripheral blood mononuclear cells, among a group of nasal S. aureus isolates, 349 
some isolates induce anti-inflammatory IL-10 production through PI3K/Akt/mTOR and 350 
Erk signalling whereas some induce pro-inflammatory TNFα through a p38-dependent 351 
pathway (Peres et al., 2015). This suggests that S. aureus manipulates different 352 
signalling cascades to initiate immune tolerance through heterogenicity expression of 353 
ligands in the process of infection.  354 
In further experiments, the treatments of heat, proteinase K, and different molecular 355 
weight cut-off fractions were examined in order to determine the nature of the anti-356 
inflammatory compounds in S. aureus supernatants. Consistent with previous studies, 357 
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the compounds were characterised as small (<3 kDa) and heat-resistant (Chekabab 358 
et al., 2015; Tajima et al., 2006). As secondary or tertiary structures of proteins are 359 
usually disrupted during boiling, the staphylococcal factors are unlikely to be proteins. 360 
Similarly, when co-stimulated with B. cenocepacia, IL-8 production elicited by 361 
proteinase K-treated S. aureus supernatants showed a 50% decrease compared to 362 
deactivated proteinase K-treated S. aureus supernatants, indicating that anti-363 
inflammatory components are less likely to be peptides due to the nonspecific 364 
protease activity of proteinase K. A possible explanation is that proteinaceous pro-365 
inflammatory components in S. aureus supernatants were degraded by proteinase K 366 
and thus the anti-inflammatory effectors overpowered the pro-inflammatory 367 
counterparts. For example, the major virulence factor SpA not only contributes to 368 
immune evasion by binding to immunoglobulin, but also elicits a strong pro-369 
inflammatory response through interacting with tumour necrosis factor receptor 1 and 370 
epidermal growth factor receptor (Gomez et al., 2004; Graille et al., 2000; Soong et 371 
al., 2011). So far only one research group reported small, heat-, and protease-resistant 372 
molecules derived from MRSA and S. epidermidis conditioned medium that induce 373 
nitric oxide in human upper airway epithelial cells (Carey et al., 2016; 2015). Although 374 
these studies did not assess production of cytokines and chemokines in response to 375 
the factors, the result strongly indicates the existence of small, heat- and protease-376 
resistant molecules that are secreted by S. aureus.  377 
We also investigated whether S. aureus factors interact with other receptors such as 378 
IL-1R and TNFR that promote the inflammatory response. The results showed that the 379 
inhibitory effect of S. aureus secreted products was B. cenocepacia stimuli-specific, 380 
as S. aureus supernatants had no effect on IL-1β / TNFα-induced IL-8 production. This 381 
is not surprising as S. aureus can colonise human airway asymptomatically, and 382 
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therefore is able to trigger a low level of inflammatory response and even suppress it 383 
in order to induce immune tolerance. Known staphylococcal factors that antagonise 384 
the vital microbial sensor TLRs, include staphylococcal superantigen-like protein 3 and 385 
TIR domain protein targeting TLR2 (Askarian et al., 2014; Koymans et al., 2017), and 386 
phenol-soluble modulin α1-3 targeting TLR4 (Chu et al., 2018). However, little is 387 
known about whether the immunosuppression of S. aureus is beneficial to the host. 388 
To further explore our findings, the impact of S. aureus on B. cenocepacia infection 389 
need to be investigated using an in vivo respiratory infection model.  Our findings for 390 
the first time illustrate the host response to S. aureus and B. cenocepacia co-infection 391 
in the airway epithelial cells, and reveal staphylococcal anti-inflammatory factors that 392 
suppress B. cenocepacia-induced IL-8 production through blocking MAPK and NF-κB 393 
signalling. To conclude, we reveal immune evasion factors secreted by S. aureus that 394 
are small, heat-stable, and non-proteinaceous, which reduce the pro-inflammatory 395 
response induced by CF-isolated B. cenocepacia in 16HBE cells. These results 396 
suggest a potential treatment for patients with chronic pulmonary infections, whereby 397 
drugs targeting MAPK and NF-κB pathways could be applied to reduce inflammation 398 
without facilitating infections. 399 
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Table 1 Bacteria strains 649 
Strain Characteristics Reference 
MRSA252 Hospital-acquired MRSA, fatal post-op 
septicemia 
Holden et al., 2004 
MSSA NCTC 
6571 
Methicillin-sensitive S. aureus  
MSSA Newman Isolated from a secondary osteomyelitis 
infection of a TB patient 
Baba et al., 2008 
MSSA209  Collins et al., 2010 
MRSA41  Collins et al., 2010 
MSSA SH1000 Laboratory strain, derivative of NCTC 8325 by 
complementation of rsbU 
O’Neill, 2010 
MSSA RN4220 Derivative of NCTC8325-4, with agrA mutation Nair et al., 2011 
MRSA USA400 Community-associated S. aureus Voyich et al., 2006 
B. cenocepacia 
J2315 
Epidemic CF-related ET12 lineage Holden et al., 2009 
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Figure 1 S. aureus supernatant has anti-inflammatory on B. cenocepacia-induced IL-8 655 
response.  656 
IL-8 production in 16HBE cells treated with B. cenocepacia (5 MOI), in the presence or 657 
absence of  (A) 10% S. aureus supernatants, or (B) heat-killed S. aureus (5 MOI) for 24 hours. 658 
The experiments were validated using (C) 10% supernatants from S. aureus isolates  or (D) 659 
heat-killed S. aureus and B. cenocepacia (MOI 5) co-stimulation for 24 hours. In (A) and (C), 660 
10% LB was used as a control. Data represent mean ± SEM of duplicate samples from three 661 
identical experiments. Significance was compared to B. cenocepacia-treated cells using 2-662 
way ANOVA followed by Dunnett’s multiple comparison test (*, p<0.05). 663 
(E) Cytotoxicity of S. aureus supernatants on 16HBE cells was assessed using MTT assay. 664 
The control was treated with 10% LB. Results are presented as a percent of the control, mean 665 
± SEM from three independent experiments. Significance was compared to the control using 666 
1-way ANOVA followed by Dunnett’s multiple comparison test. 667 
 668 
Figure 2 Effect of S. aureus supernatants on by B. cenocepacia-activated MAPK and 669 
NF-κB signalling. 670 
16HBE cells were infected by B. cenocepacia unwashed culture at an MOI of 5 for the 671 
indicated time. TNFα (20 ng/mL) for 5 minutes was used as the positive control. (A) Western 672 
blot analysis for levels of phosphorylated p38, phosphorylated Erk, phosphorylated p65, and 673 
p38 in cell lysate followed by B. cenocepacia stimulation. Phosphorylation of p38 (B), ERK 674 
(C), p65 (D) of cell lysates were measured by western blot and normalised against total p38.  675 
16HBE cells were treated with 10% LB as the control, B. cenocepacia (5 MOI), with the 676 
presence or absence of 10% S. aureus supernatant for 2 hours. (E) Western blot analysis for 677 
levels of phosphorylated p38, phosphorylated Erk, phosphorylated p65, and p38 in cell lysate 678 
following S. aureus supernatants and B. cenocepacia co-stimulation. Phosphorylation of p38 679 
 26 
(F), Erk (G) and p65 (H) of cell lysates were measured using western blot and normalised 680 
against total p38. 681 
Protein bands representative of three independent experiments. Data are shown as mean ± 682 
SEM. *, p<0.05 significant reduction compared to B. cenocepacia-treated group using 2-way 683 
ANOVA followed by a one-tailed Dunnett’s multiple comparisons test. 684 
 685 
Figure 3 Characterisation of anti-inflammatory components in S. aureus supernatants. 686 
16HBE cells were treated with B. cenocepacia (5 MOI), in the presence or absence of 10% 687 
(A) heat-treated supernatants, (B) proteinase K (PK)-treated S. aureus supernatants, (C) S. 688 
aureus supernatant fractions containing metabolites of >10 kDa, >3 kDa, and <3 kDa for 24 689 
hours. IL-8 production was analysed using ELISA. Data represent mean ± SEM from 3 690 
independent experiments performed in duplicate. *, p<0.05 significance compared to B. 691 
cenocepacia-treated group using 2-way ANOVA followed by Dunnett’s multiple comparisons 692 
test.  693 
(D) 16HBE cells were co-treated with IL-1 (1 ng/mL) / TNFα (10 ng/mL) and 10% S. aureus 694 
supernatants for 24 hours. B. cenocepacia (5 MOI) was the positive control. Data represent 695 
mean ± SEM from 3 independent experiments performed in duplicate. *, p<0.05 compared to 696 
IL-1β / TNFα-treated group or with IL-1/ TNFα -treated group using 2-way ANOVA followed 697 
by Tukey’s multiple comparisons test.   698 
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Figure 2 721 
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Figure 3 723 
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